Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: A randomized placebo-controlled trial

Jill P. Smith, Sandra I. Bingaman, Francesca Ruggiero, David T. Mauger, Aparna Mukherjee, Christopher O. McGovern, Ian S. Zagon

Research output: Contribution to journalArticlepeer-review

73 Scopus citations

Abstract

Background: Endogenous opioid peptides have been shown to play a role in the development and/or perpetuation of inflammation. We hypothesize that the endogenous opioid system is involved in inflammatory bowel disease, and antagonism of the opioid-opioid receptor will lead to reversal of inflammation. Aims: A randomized double-blind placebo-controlled study was designed to test the efficacy and safety of an opioid antagonist for 12 weeks in adults with active Crohn's disease. Methods: Forty subjects with active Crohn's disease were enrolled in the study. Randomized patients received daily oral administration of 4.5-mg naltrexone or placebo. Providers and patients were masked to treatment assignment. The primary outcome was the proportion of subjects in each arm with a 70-point decline in Crohn's Disease Activity Index score (CDAI). The secondary outcome included mucosal healing based upon colonoscopy appearance and histology. Results: Eighty-eight percent of those treated with naltrexone had at least a 70-point decline in CDAI scores compared to 40% of placebo-treated patients (p = 0.009). After 12 weeks, 78% of subjects treated with naltrexone exhibited an endoscopic response as indicated by a 5-point decline in the Crohn's disease endoscopy index severity score (CDEIS) from baseline compared to 28% response in placebo-treated controls (p = 0.008), and 33% achieved remission with a CDEIS score <6, whereas only 8% of those on placebo showed the same change. Fatigue was the only side effect reported that was significantly greater in subjects receiving placebo. Conclusions: Naltrexone improves clinical and inflammatory activity of subjects with moderate to severe Crohn's disease compared to placebo-treated controls. Strategies to alter the endogenous opioid system provide promise for the treatment of Crohn's disease.

Original languageEnglish (US)
Pages (from-to)2088-2097
Number of pages10
JournalDigestive Diseases and Sciences
Volume56
Issue number7
DOIs
StatePublished - Jul 2011

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: A randomized placebo-controlled trial'. Together they form a unique fingerprint.

Cite this